Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26891081.
- Also identified by DOI 10.1002/adhm.201500993 and PMC identifier 4864113.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Delivering syndecan-4 with FGF-2 improves the effectiveness of FGF-2 therapy for ischemia in the diabetic disease state. The syndecan-4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan-4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype.
Medical subject headings
- Diabetes Mellitus, Experimental
- Diabetes Mellitus, Type 2
- Hindlimb
- Ischemia
- Neovascularization, Physiologic
- Syndecan-4